FindTrial
Sign In

Pain killer administration and gastritis

comparison of gastric tolerability of ulcerogenic drugs administered just before and after food

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/03/005632
Enrollment
160
Registered
2015-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Gastritis

Interventions

Intervention1: diclofenac or etodolac sustained release tablet. either of these two may be given: diclofenac 75-100mg twice daily or etodolac sustained release tablet 600mg once daily administered ju

Sponsors

self funded
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients recieving NSAIDs

Exclusion criteria

Exclusion criteria: Patients receiving drugs for Hyperacidity

Design outcomes

Primary

MeasureTime frame
development of symptoms of gastritisTimepoint: 2 days—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Padmaja Udaykumar

Father Muller Medical College

padmajaudaykumar@gmail.com9880890512

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026